Heart BMJ

FEBRUARY 12, 2025

Fabry disease (FD) is a rare X-linked genetic lysosomal storage disorder characterised by glycosphingolipid accumulation leading to multiorgan involvement including the heart typically in the second to fourth decades of life.

Exercise 52

Exercise Preserved Ejection Fraction Cardiomyopathy Heart Failure 52

Frontiers in Cardiovascular Medicine

JANUARY 20, 2025

ObjectiveThe aim of this retrospective study was to evaluate the usefulness of non-contrast cardiac magnetic resonance imaging, including cine imaging, T1 and T2 mapping, and texture analysis for T1 mapping, for identifying etiologies of heart failure (HF).MethodsForty-seven MethodsForty-seven patients with HF were examined using a 1.5T

Heart Failure 52

Heart Failure Cardiomyopathy Tachycardia Hypertension 52

European Journal of Heart Failure

DECEMBER 5, 2024

Breakdown of the study population by worsening heart failure (WHF) event proportions (oral diuretic intensification or heart failure [HF] hospitalization) and KaplanMeier curve of all-cause mortality after WHF event shown, relative to a patient group that did not have any WHF events.

Outpatient 75

Outpatient Heart Failure Cardiomyopathy Atrial Fibrillation 75

Med Page Today

SEPTEMBER 30, 2024

(MedPage Today) -- There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial. An established cardiac myosin inhibitor for hypertrophic cardiomyopathy.

Preserved Ejection Fraction 98

Preserved Ejection Fraction Heart Failure Cardiomyopathy 98

Circulation

APRIL 13, 2025

Heart failure is a growing health-care concern affecting tens of millions of individuals globally. Although traditional therapeutic strategies have focused on reducing the risk for hospitalization and mortality, the importance of patient-reported outcomes (PROs) in patients with heart failure is increasingly being recognized.

Heart Failure 81

Heart Failure Outcomes Article Cardiomyopathy 81

Frontiers in Cardiovascular Medicine

MARCH 7, 2024

However, information on its efficacy and safety in patients with heart failure remains limited. Case presentation A 43-year-old man with a body mass index of 41 kg/m 2 was admitted to our hospital for acute heart failure due to dilated cardiomyopathy. No adverse events were observed during B-SES.

Heart Failure 124

Heart Failure Obesity Heart Transplant Transplant 124

Cardiovascular Diabetology

SEPTEMBER 15, 2024

Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. During the 4.22-year

Obesity 98

Obesity Heart Failure Diabetes Cardiomyopathy 98

DAIC

JANUARY 22, 2024

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG , announced that it is initiating GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase 2 trial of AB-1002 (also known as NAN-101 ) for the treatment of congestive heart failure (CHF). Heart failure. Published 2022.

Heart Failure 105

Heart Failure Public Health Cardiomyopathy 105

American College of Cardiology

MARCH 30, 2025

For his groundbreaking work in gene discovery and identification, growing three different programs as a pediatric cardiology chief and his development of three separate high-level cardiomyopathy, heart failure (HF) and transplant programs, Towbin received the ACC Lifetime Achievement Award during ACC.25

Pediatrics 63

Pediatrics Transplant Heart Failure Cardiomyopathy 63

European Journal of Heart Failure

DECEMBER 13, 2023

Aim The value of disease-modifying therapies (such as tafamidis) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and severe heart failure symptoms has been debated. Clinical Trial Registrations: ClinicalTrials.gov NCT01994889 and NCT02791230.

Heart Failure 75

Heart Failure Cardiomyopathy 75

European Journal of Heart Failure

FEBRUARY 5, 2025

Long-term follow-up (FU) of the TRED-HF trial: persistent high-risk of relapse following therapy withdrawal in recovered dilated cardiomyopathy (DCM), likely contributed to by low-dose therapy and exposure to external triggers. LVEF, left ventricular ejection fraction. This follow-up investigates the longer-term effects of therapy withdrawal.

Heart Failure 67

Heart Failure Cardiomyopathy Atrial Fibrillation Arrhythmia 67

DAIC

MAY 6, 2024

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Journal of Clinical Investigation - Cardiology

FEBRUARY 17, 2025

Heterozygous truncating variants in the sarcomere protein titin (TTN) are the most common genetic cause of heart failure. Moreover, isogenic hiPSC-CMs containing a rare E1 variant in the predicted MEF2-binding motif that was identified in a patient with unexplained dilated cardiomyopathy (DCM) showed reduced TTN expression.

CMS 75

CMS Heart Failure Cardiomyopathy 75

Frontiers in Cardiovascular Medicine

APRIL 10, 2025

Dilated cardiomyopathy (DCM) is characterized by impaired expansion or contraction of the left or both ventricles in the absence of abnormal load conditions (such as primary valve disease) or severe coronary artery disease that can lead to ventricular remodeling. Up to 40% of DCM cases involve probable or confirmed genetic variations.

Heart Failure 40

Heart Failure Cardiomyopathy Coronary Artery Disease Atherosclerosis 40

Circulation

JANUARY 27, 2025

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

Heart Disease 81

Heart Disease Peripheral Arterial Disease Stroke Strokes 81

JAMA Cardiology

JUNE 25, 2024

This genetic association study evaluates the association of genetic variants with atrial fibrillation, cardiomyopathy, and heart failure.

Atrial Fibrillation 103

Atrial Fibrillation Heart Failure Cardiomyopathy 103

DAIC

JUNE 4, 2024

American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged 3.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Peripheral Arterial Disease Heart Failure Atrial Fibrillation 105

Circulation: Heart Failure

DECEMBER 18, 2023

Circulation: Heart Failure, Volume 16, Issue 12 , Page e010351, December 1, 2023. Recent evidence suggests that loss of PRDM16 expression is associated with cardiomyopathy development in mice, although its role in human cardiomyopathy development is unclear.

Cardiomyopathy 75

Cardiomyopathy Heart Failure Pediatrics Circulation 75

Frontiers in Cardiovascular Medicine

JANUARY 3, 2024

Hypertrophic cardiomyopathy is the most common genetic cardiac disorder and is defined by the presence of left ventricular (LV) hypertrophy in the absence of a condition capable of producing such a magnitude of hypertrophy. Over the past decade, guidelines on the screening, diagnostic, and management protocols of pediatric primary (i.e.,

Pediatrics 87

Pediatrics Cardiomyopathy Exercise Heart Failure 87

DAIC

MARCH 26, 2024

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, 24, taking place April 6-8, 2024 in Atlanta, Georgia. 24 , taking place April 6-8, 2024 in Atlanta, Georgia.

Cardiomyopathy 104

Cardiomyopathy Research Heart Failure Hospital 104

Medical Xpress - Cardiology

OCTOBER 10, 2024

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in patients with heart failure with preserved ejection fraction.

Preserved Ejection Fraction 97

Preserved Ejection Fraction Biomarkers Heart Failure Cardiomyopathy 97

American College of Cardiology

JULY 12, 2024

What are the racial and ethnic differences among individuals with diabetic dilated cardiomyopathy at high risk for overt heart failure?

Cardiomyopathy 53

Cardiomyopathy Diabetes Heart Failure Article 53

Dr. Smith's ECG Blog

JANUARY 2, 2025

And of course Ken's comments at the bottom) An elderly obese woman with cardiomyopathy, Left bundle branch block, and chronic hypercapnea presented hypoxic with altered mental status. I do not see OMI here and all trops were only minimally elevated, consistent with either chronic injury from cardiomyopathy or with acute injury from sepsis.

Tachycardia 116

Tachycardia Cardiomyopathy Blog Bradycardia 116

Frontiers in Cardiovascular Medicine

JANUARY 16, 2024

Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Conclusions Therefore, catheter ablation proves to be effective in providing long-term control of atrial fibrillation in patients with dilated cardiomyopathy.

Atrial Fibrillation 64

Atrial Fibrillation Ablation Cardiomyopathy Heart Failure 64

Heart BMJ

NOVEMBER 27, 2023

Objective Heart failure (HF) is one of the most common and lifestyle-limiting complications of hypertrophic cardiomyopathy (HCM). Prediction of worsening HF using clinical measures alone remains limited. Moreover, the mechanisms by which patients with HCM develop worsening HF have not been elucidated.

Heart Failure 52

Heart Failure Cardiomyopathy 52

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

We aimed to associate the levels of SN in plasma with different causes of heart failure. Methods We prospectively enrolled consecutive patients with ischaemic (ICM) and dilated (DCM) cardiomyopathy from the outpatient heart failure clinic and healthy individuals. Results A total of 53 patients (81.1%

Cardiomyopathy 59

Cardiomyopathy Heart Failure Outpatient Biomarkers 59

Cardiovascular Diabetology

APRIL 24, 2024

Diabetic cardiomyopathy (DCM) poses a growing health threat, elevating heart failure risk in diabetic individuals. Understanding DCM is crucial, with fibroblasts and endothelial cells playing pivotal roles in.

Cardiomyopathy 59

Cardiomyopathy Diabetes Heart Failure Research 59

Dr. Smith's ECG Blog

APRIL 2, 2024

I was there and said, "No, I think this is all due to severe chronic cardiomyopathy and cardiac arrest due to primary ventricular fibrillation, not due to ACS." _ Why did I say that? Patient has an ICD, which is primarily placed in patients with cardiomyopathy. The bedside echo showed dilated cardiomyopathy with relatively thin walls.

Tachycardia 132

Tachycardia Pacemaker Cardiac Arrest Cardiomyopathy 132

Cardiovascular Diabetology

JANUARY 19, 2024

Diabetes mellitus (DM) is associated with a worse prognosis in patients with heart failure. Our aim was to analyze the clinical and imaging features of patients with DM and their association with outcomes in c.

Diabetes 95

Diabetes Outcomes Heart Failure Cardiomyopathy 95

American College of Cardiology

JULY 2, 2024

What is the effect of AT-001, an aldose reductase inhibitor, on exercise capacity among individuals with diabetic cardiomyopathy (DbCM) with reduced exercise capacity and at high risk for progression to overt heart failure (HF)?

Cardiomyopathy 50

Cardiomyopathy Diabetes Exercise Heart Failure 50

DAIC

APRIL 9, 2024

Decline in exercise ability is a hallmark of progression to overt heart failure. The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy. Patients had had Type 2 diabetes for an average of 14 years.

Heart Failure 52

Heart Failure Diabetes Cardiomyopathy Exercise 52

European Journal of Heart Failure

DECEMBER 18, 2024

Impact of guideline-directed medical therapy for heart failure after left ventricular ejection fraction (LVEF) improvement in arrhythmia-induced cardiomyopathy. ( A ) Study flow chart. ( B ) Changes in renin-angiotensin-system (RAS) inhibitors and beta-blockers (BB) prescriptions after LVEF improvement. (

Heart Failure 40

Heart Failure Arrhythmia Cardiomyopathy Research 40

Frontiers in Cardiovascular Medicine

JUNE 28, 2024

Septic cardiomyopathy, a life-threatening complication of sepsis, can cause acute heart failure and carry a high mortality risk. These exosomes can both diagnose and treat septic cardiomyopathy, playing a crucial role in its development and progression. Current treatments have limitations.

Cardiomyopathy 52

Cardiomyopathy Article Technology Cardiac Function 52

Circulation: Heart Failure

FEBRUARY 10, 2025

Circulation: Heart Failure, Ahead of Print. Changes in TTN expression are associated with cardiac dysfunction, and TTN is one of the main genes linked to dilated cardiomyopathy (DCM).

Cardiomyopathy 68

Cardiomyopathy Heart Failure Circulation 68

Cardiovascular Diabetology

AUGUST 1, 2024

Persons with diabetes are at risk for developing a cardiomyopathy through several pathophysiological mechanisms independent of traditional risk factors for heart failure. Among those with diabetic cardiomyopat.

Cardiomyopathy 52

Cardiomyopathy Heart Failure Risk Factors Diabetes 52

Circulation: Genomic and Precision Medicine

JANUARY 30, 2024

BACKGROUND:Pathogenic variants in PKP2 (plakophilin-2) cause arrhythmogenic right ventricular cardiomyopathy, a disease characterized by life-threatening arrhythmias and progressive cardiomyopathy leading to heart failure. Circulation: Genomic and Precision Medicine, Ahead of Print.

Cardiomyopathy 72

Cardiomyopathy Arrhythmia Cardiac Function Heart Failure 72

Open Heart

DECEMBER 6, 2023

Objectives In hypertrophic cardiomyopathy (HCM), specific ECG abnormalities are observed. Although several studies have reported on estimating the risk of developing fatal arrhythmias from ECG findings, the use of ECG to identify the severity of heart failure (HF) by applying deep learning (DL) methods has not been established.

Heart Failure 52

Heart Failure Cardiomyopathy Electrocardiogram Arrhythmia 52